ESM Technologies is pleased to announce a new independent clinical trial has published evaluating the joint health ingredient NEM® brand eggshell membrane.
An independent, multi-center clinical trial conducted in Germany by Weber & Weber GmbH and Co. KG confirmed the rapid results found with NEM® brand eggshell membrane in prior clinical trials. The six-center study recruited 44 subjects with moderate, persistent knee and/or hip discomfort. The study participants were supplemented once daily with a capsule containing 500 mg of NEM® for 60 days and were evaluated at 10, 30, & 60 days using a short-form questionnaire based upon the WOMAC questionnaire. The researchers found statistically significant results as early as 10 days, with nearly one-quarter of the participants feeling at least a 30% improvement in this short time. The improvement continued to the end of the study with more than 59% of the participants rating NEM’s efficacy as good or very good. There were no serious adverse events in the study and NEM® was reported to be well tolerated. The researchers concluded that this trial validates the clinical results seen with NEM® previously and that NEM® provides a viable natural treatment option for the broader European population. The results of the peer-reviewed study were recently published online (doi:10.4172/2167-7921.1000136).
“We’re always pleased when an independent study is conducted that corroborates our own clinical results, particularly when it confirms NEM’s fast onset of efficacy. The German researchers did an excellent job of validating NEM’s safety & efficacy, as well as patient acceptance, in a European population.” commented Kevin J. Ruff Ph.D., MBA, CCRP – Director of Scientific & Regulatory Affairs for ESM Technologies.
